1.60
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.64
Offen:
$1.64
24-Stunden-Volumen:
1.99M
Relative Volume:
1.11
Marktkapitalisierung:
$159.65M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-37.34M
KGV:
-1.1765
EPS:
-1.36
Netto-Cashflow:
$-36.91M
1W Leistung:
-10.11%
1M Leistung:
-8.05%
6M Leistung:
+44.14%
1J Leistung:
+13.48%
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Firmenname
Sellas Life Sciences Group Inc
Sektor
Branche
Telefon
(646) 200-5278
Adresse
7 TIMES SQUARE, NEW YORK, NY
Vergleichen Sie SLS mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
SLS
Sellas Life Sciences Group Inc
|
1.60 | 177.60M | 0 | -37.34M | -36.91M | -1.36 |
![]()
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2021-07-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
2018-11-01 | Eingeleitet | Oppenheimer | Outperform |
2018-04-02 | Eingeleitet | H.C. Wainwright | Buy |
2018-03-19 | Hochstufung | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Aktie (SLS) Neueste Nachrichten
Northern Trust Corp Acquires 33,878 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World
SELLAS reports potential colorectal cancer therapy progress By Investing.com - Investing.com South Africa
SELLAS reports potential colorectal cancer therapy progress - Investing.com India
Sellas Life Sciences Group, Inc. Presents Preclinical Efficacy of Sls009 in Asxl1 Mutated Colorectal Cancer At 2025 Asco Annual Meeting - marketscreener.com
SELLAS Life Sciences (SLS) Highlights Promising Results for SLS009 in Cancer Study | SLS Stock News - GuruFocus
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting - GlobeNewswire
Breakthrough at ASCO: SELLAS Drug Shows Powerful Response in Targeted Colorectal Cancer Treatment - Stock Titan
Insider Buying: Katherine Kalin Acquires 20,000 Shares of SELLAS Life Sciences Group Inc (SLS) - GuruFocus
US futures and global markets tumble after Trump threatens European Union with 50% tariffs and Apple with 25% tariff - The Globe and Mail
Director Makes Bold Move with Major Stock Purchase in SELLAS Life Sciences Group - TipRanks
Sellas Life Sciences Reports Improved Financial Position - TipRanks
SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase - The Manila Times
SELLAS Life Sciences CEO to Reveal Latest Cancer Drug Development Strategy at Major Healthcare Conference - Stock Titan
Sellas doses first paediatric subject with AML in Phase II trial of SLS009 - Yahoo Finance
SELLAS advances pediatric AML treatment with Phase 2 trial By Investing.com - Investing.com South Africa
Sellas Life Sciences Doses 1st Pediatric Patient in Acute Myeloid Leukemia Study - marketscreener.com
SELLAS Life Sciences (SLS) Advances Phase 2 Trial for Pediatric AML | SLS Stock News - GuruFocus
SELLAS advances pediatric AML treatment with Phase 2 trial - Investing.com
SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML - GlobeNewswire
Breakthrough: First Child with Resistant Leukemia Receives New Treatment in Major Clinical Trial - Stock Titan
SELLAS Life Sciences (SLS) Reports Improved Q1 Earnings Amid Fin - GuruFocus
SLS009 Shows Promising Results in Latest AML Trials | SLS Stock News - GuruFocus
SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
SELLAS Life Sciences Group Reports Positive Overall Survival Data for SLS009 in r/r AML and Updates on Financial Position and Pipeline Developments - Nasdaq
SELLAS Life Sciences (SLS) Reports Improved Q1 Earnings Amid Financial Boost - GuruFocus
Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight - GlobeNewswire Inc.
SELLAS Life Sciences Group (SLS) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Upward Trajectory: SELLAS Life Sciences Group Inc (SLS) Posts a Gaine, Closing at 1.72 - DWinneX
Financial Metrics Exploration: Understanding SELLAS Life Sciences Group Inc (SLS) Through Ratios - DWinneX
Geode Capital Management LLC Purchases 128,355 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World
Wall Street analysts’ outlook for SELLAS Life Sciences Group Inc (SLS) - Sete News
SELLAS Life Sciences Group Inc’s latest rating changes from various analysts - knoxdaily.com
SELLAS Life Sciences Group Inc (SLS) Stock: The Story of a 52-Week Stock Range - investchronicle.com
Understanding the Risks of Investing in La Rosa Holdings Corp (LRHC) - knoxdaily.com
SELLAS reports promising AML treatment in preclinical study - Investing.com
SELLAS Life Sciences (SLS) Reports Promising Preclinical Results for SLS009 in Leukemia | SLS Stock News - GuruFocus
SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference - The Manila Times
Breakthrough: New Cancer Drug SLS009 Extends AML Patient Survival by 252% in Clinical Trial Data - Stock Titan
SELLAS Life Sciences Group Inc: Navigating Market Fluctuations with a 127.18M Market Cap - investchronicle.com
The time has not yet come to remove your chips from the table: SELLAS Life Sciences Group Inc (SLS) - Sete News
BILI Shares Experience Surge in Value - knoxdaily.com
SLSSellas Life Sciences Group Inc Latest Stock News & Market Updates - Stock Titan
Ratio Review: Analyzing fuboTV Inc (FUBO)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Financial Fitness Check: Examining Royalty Pharma plc (RPRX)’s Key Ratios - DWinneX
SELLAS Life Sciences Group (NASDAQ:SLS) Trading 1.6% Higher – Time to Buy? - Defense World
Amazon's Earnings Could Fuel a Rapid Breakout - The Globe and Mail
SELLAS Life Sciences Group, Inc. to Present Preclinical Efficacy Data for SLS009 in ASXL1 Mutated Colorectal Cancer at ASCO 2025 Annual Meeting - Nasdaq
SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewswire
Clinical Trial Breakthrough: SELLAS Unveils Novel Cancer Drug Results for Hard-to-Treat ASXL1 Mutations - Stock Titan
How did SELLAS Life Sciences Group Inc (SLS) fare last session? - uspostnews.com
Analysts review SELLAS Life Sciences Group Inc’s rating - knoxdaily.com
Finanzdaten der Sellas Life Sciences Group Inc-Aktie (SLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):